Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Analisi di costo efficacia di emtricitabina/tenofovir disoproxil più efavirenz rispetto ad altri regimi antiretrovirali nel trattamento di prima linea di pazienti affetti da HIV, Giornale Italiano di Health Technology Assessment, July 2010, Springer Science + Business Media,
DOI: 10.1007/bf03320728.
You can read the full text:

Read

Contributors

The following have contributed to this page